Mounjaro 2.5 mg weight loss first month starting dose and progress infographic by Dr Moxit Shah DM Endocrinology, Vishuddha Diabetes Thyroid Weight Loss Clinic Ahmedabad
|

Mounjaro 2.5 mg Not Working for Weight Loss? First-Month Results, Doses & What to Do

By Dr. Moxit Shah, DM Endocrinology
Vishuddha Diabetes, Thyroid, Weight Loss Clinic, Ahmedabad

Medically reviewed for publication: November 2026. Based on India-approved product information and published SURMOUNT clinical trials.

“I started Mounjaro 2.5 mg for weight loss, but the weighing scale is barely moving. Is the medicine not working?” This is a common concern in the first few weeks of tirzepatide treatment. The most important point is that Mounjaro 2.5 mg is a starting dose, used to introduce the medicine gradually and improve tolerability. It is not the usual long-term maintenance dose for weight management.

Some people notice reduced hunger and early weight changes at 2.5 mg. Others see little change in the first four weeks. Neither experience alone predicts how much weight a person will lose over the full course of treatment. Mounjaro works best as part of a medically supervised programme that includes suitable nutrition, physical activity and ongoing assessment—not as a race to the highest dose.

Quick answer: If you have not lost much weight after four weeks on Mounjaro 2.5 mg, that does not automatically mean treatment has failed. Review your symptoms, food intake, weight trend and tolerability with your prescriber. Product guidance generally starts with 2.5 mg once weekly for four weeks, then 5 mg once weekly; any further escalation depends on response and tolerance and should be clinician-directed.

What is Mounjaro, and how does it support medical weight loss?

Mounjaro is the brand name for tirzepatide, a once-weekly medicine acting on both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. These signals influence appetite, satiety, blood glucose regulation and gastric emptying.

Mounjaro was launched in India in 2025 for type 2 diabetes and chronic weight management under CDSCO authorization. It is available as a prescription medicine, including a KwikPen presentation containing four weekly doses. Its use for medical weight management should be assessed against the India-approved indication; it is not intended for casual or cosmetic weight loss.

Read our overview: Mounjaro (Tirzepatide) for Diabetes and Weight Loss.

Why is Mounjaro 2.5 mg called the starting dose?

The standard initiation schedule begins at 2.5 mg once weekly for four weeks. The dose is then usually increased to 5 mg once weekly, if appropriate and tolerated. Additional increases, when needed, are made in 2.5 mg steps no more frequently than every four weeks on the current dose. For adult weight management, product guidance identifies 5 mg, 10 mg and 15 mg as maintenance doses; 15 mg once weekly is the maximum adult dose.

This careful approach helps manage nausea, vomiting, fullness, constipation, diarrhoea and other gastrointestinal symptoms. Increasing too rapidly may worsen side effects without providing a safe or predictable benefit.

Treatment stage Usual dose in product guidance What it means
Weeks 1–4 2.5 mg once weekly Introduction and tolerability; weight response varies
From week 5 5 mg once weekly, when appropriate First recommended maintenance-dose option
Later, if needed 7.5, 10, 12.5 and up to 15 mg Stepwise increases of 2.5 mg, with at least four weeks between increases
Long-term plan Individualized, commonly 5, 10 or 15 mg Balance effectiveness, side effects, goals and ongoing benefit

Important: This table explains labelled dosing principles, not a prescription or a requirement to reach 15 mg. Do not double a dose, escalate early, or change your medicine simply because your weight has not changed during one week. Refer to the specific India-approved product instructions and your clinician’s treatment plan.

Why might weight loss be slow during the first month?

1. Your body is adjusting to the starter dose

The 2.5 mg period is intended primarily for initiation and tolerability. A large average weight reduction observed after many months in clinical trials should not be used as a promise for the first four weeks.

2. Weight changes fluctuate from water, meals and bowel movements

Body weight can vary from day to day with fluid intake, salt, constipation, menstruation and timing of meals. An isolated reading may hide a gradual trend. Compare weights under similar conditions rather than weighing repeatedly throughout the day.

3. Appetite change does not automatically guarantee a calorie deficit

Some people feel less hungry but still consume energy-dense foods or sweet beverages. A diet review can identify manageable improvements without imposing an extreme or nutritionally poor eating pattern.

4. Sleep, activity and medications can affect progress

Irregular sleep, low activity levels, certain prescription drugs, hormonal conditions and other health factors may contribute. Your endocrinologist should evaluate relevant issues rather than simply labelling the patient a non-responder.

5. Digestive side effects may change eating and hydration

Constipation and bloating may affect how a person feels and what the weighing scale shows. Severe vomiting or dehydration is not a sign of better treatment; it requires medical attention.

6. An individual’s response is different from a trial average

Age, baseline weight, body composition, diabetes status, adherence, lifestyle and the maximum tolerated dose all influence outcome. Some people respond earlier and some later. There is no reliable single “expected kilograms” target for everybody after exactly four injections.

Our article about weight-loss plateaus on GLP-1 medicines explains how to distinguish a genuine plateau from normal fluctuations.

How much weight loss is possible with tirzepatide over time?

The largest studies measured outcomes after months of treatment at maintenance doses, combined with lifestyle support. It is essential to keep those conditions in mind when interpreting the results.

SURMOUNT-1: Adults without diabetes

In the 72-week SURMOUNT-1 randomized trial, mean weight reductions in the treatment-regimen analysis were:

Assigned weekly treatment Average body-weight change at 72 weeks
Tirzepatide 5 mg −15.0%
Tirzepatide 10 mg −19.5%
Tirzepatide 15 mg −20.9%
Placebo plus lifestyle intervention −3.1%

Example for understanding percentages, not a prediction: A 100 kg person who lost 15% would weigh approximately 85 kg. A 20% reduction would mean about 80 kg. Individual results vary considerably. These figures are 72-week trial averages—not weight-loss expectations after one month on 2.5 mg.

SURMOUNT-2: Adults with type 2 diabetes

In the 72-week SURMOUNT-2 study, people with type 2 diabetes and excess weight achieved mean weight reductions of 12.8% with 10 mg and 14.7% with 15 mg, versus 3.2% with placebo. This shows why diabetes status and trial population matter when comparing percentages.

Read more about GLP-1 weight loss: what to expect month by month.

What should you track during your first four weeks on Mounjaro?

Rather than checking only the number on the scale, discuss a simple treatment-monitoring plan with your endocrinologist.

What to track Why it matters
Weekly body weight Helps reveal trends rather than daily fluid fluctuations
Waist measurement Provides another indicator of change in central body size
Appetite and fullness Shows whether satiety patterns are changing
Protein intake and food quality Supports nutritional adequacy during reduced food intake
Walking and resistance exercise Supports fitness and preservation of muscle function
Digestive symptoms and hydration Helps identify dose-related side effects before escalation
Glucose readings, if you have diabetes Supports medication safety, especially if using insulin or sulfonylureas

A practical weighing method: Choose one morning each week, use the same scale, and measure under similar conditions. Avoid obsessive weighing or treating every small increase as treatment failure.

What to eat while taking Mounjaro for weight loss in India

A nutritionally balanced plan matters because appetite suppression can lead some patients to eat too little protein or skip meals repeatedly. Healthy weight loss should protect muscle, energy and overall nutritional status.

  • Include protein-rich foods: for example, dal, chickpeas, rajma, soy, tofu, paneer, milk or curd as appropriate for your nutritional needs.
  • Use vegetables and fibre-containing foods: choose portions that your digestive system tolerates, particularly if nausea or bloating occurs.
  • Choose manageable portions: smaller meals may help with early fullness. Avoid large high-fat meals if they aggravate symptoms.
  • Drink fluids regularly: unless your doctor has prescribed a fluid restriction. Seek help if vomiting or diarrhoea prevents adequate hydration.
  • Add resistance training when safe: strength-building activity may help preserve muscle while body weight decreases.
  • Avoid crash dieting: it can worsen fatigue and raise the risk of nutritional deficiencies and gallstones.

For vegetarian meal ideas, see our Indian food guide for patients taking GLP-1 medicines.

When should the Mounjaro dose be increased?

The labelled schedule allows a move from 2.5 mg to 5 mg after four weeks. Subsequent increases may be considered at intervals of at least four weeks when clinically appropriate, based on treatment response and tolerability.

More is not always better for an individual. If nausea, poor oral intake, significant constipation or other symptoms persist, your clinician may need to review the regimen. For some patients, staying at an effective, tolerated maintenance dose is preferable to escalating purely to reach 15 mg.

It is also important to review whether your treatment is achieving clinically meaningful goals at an appropriate stage. Guidance in some jurisdictions recommends reassessing continuation if at least 5% initial weight loss has not occurred six months after titration to the highest tolerated dose, taking the overall benefit and risk into account. This is not an instruction to stop after the first few weeks.

If the medicine is interrupted or several doses are missed, do not automatically restart at the previous high dose without prescriber advice. Read our missed tirzepatide dose guidance.

Who is eligible for Mounjaro for medical weight loss in India?

According to Lilly India’s announcement of CDSCO authorization, Mounjaro is approved for chronic weight management in adults as an adjunct to diet and exercise when the initial body mass index (BMI) is:

  • 30 kg/m² or above; or
  • 27 kg/m² or above with at least one weight-related condition, such as type 2 diabetes, hypertension or dyslipidaemia.

These are the product-authorization criteria stated by the manufacturer. Lower Asian Indian BMI thresholds used to identify metabolic risk are not automatically the same as the approved prescribing thresholds for this medicine. Your doctor should assess the full clinical picture and the exact current India-approved label.

Mounjaro should not be used merely for a small cosmetic change or without professional supervision. Read our Weight Loss Doctor in Ahmedabad: Medical GLP-1 Treatment guide.

What is the Mounjaro 2.5 mg price in India?

As a dated reference, Lilly India’s KwikPen launch announcement dated 12 August 2025 listed a maximum retail price of ₹14,000 for a four-dose 2.5 mg KwikPen and ₹17,500 for the four-dose 5 mg KwikPen. The announcement also listed higher-strength pens at higher prices.

These are manufacturer-published launch MRPs, not a verified live price quotation for November 2026. Current MRP, local pharmacy price, available pack, taxes and stock should be confirmed with an authorized pharmacy before purchasing. Medication, consultation and monitoring costs may all contribute to an individual’s overall treatment budget.

See the original Lilly India KwikPen launch notice for the dated MRP table.

Important side effects and safety checks before Mounjaro

Common side effects include nausea, diarrhoea, constipation, indigestion, abdominal discomfort and vomiting, especially during initiation and dose escalation. A clinician should review personal and family history, current medicines, pregnancy intentions and the potential for medication interactions before treatment.

Seek urgent medical assessment for severe or persistent abdominal pain, particularly if it radiates to the back, repeated vomiting, signs of dehydration, jaundice or serious allergic reactions. Gallbladder disease and pancreatitis require particular attention. If you have diabetes and use insulin or a sulfonylurea, changes to the diabetes regimen may be needed to reduce hypoglycaemia risk.

U.S. tirzepatide labelling includes a warning about thyroid C-cell tumours observed in rodents and lists personal or family history of medullary thyroid carcinoma (MTC), or multiple endocrine neoplasia syndrome type 2 (MEN2), as contraindications. Country-specific labels and clinical histories must be reviewed. Ordinary hypothyroidism is not the same condition as MTC or MEN2.

Tirzepatide is not a treatment for use in pregnancy. It can affect the absorption of oral hormonal contraceptives; label guidance advises non-oral or additional barrier contraception for four weeks after initiation and dose escalation. Read our Mounjaro and birth control pills article for details.

Frequently asked questions: Mounjaro 2.5 mg weight loss

1. Is it normal not to lose weight on Mounjaro 2.5 mg?

It can happen. The 2.5 mg dose is a starter dose, and response during the first four weeks varies. A lack of rapid change does not alone indicate treatment failure. Discuss progress and tolerability at your follow-up appointment.

2. How many kilograms should I lose in the first month?

There is no reliable fixed number for everyone. Trial results after 72 weeks at assigned maintenance doses are not a prediction for one month at 2.5 mg. Your initial body weight, appetite, food intake, glucose status and other factors all affect the trend.

3. Does Mounjaro start working immediately?

Tirzepatide begins acting pharmacologically after administration, but visible weight reduction can take time. Appetite changes and weight changes may not occur at the same pace.

4. Can I move directly from 2.5 mg to 10 mg?

No—not as a routine self-directed step. Product guidance uses a gradual, clinician-supervised escalation pathway to reduce gastrointestinal side effects.

5. Is 5 mg better than 2.5 mg for weight loss?

For adult weight management, 5 mg is a recommended maintenance-dose option, whereas 2.5 mg is used for initiation. The appropriate dose depends on medical history, response and tolerability.

6. Do I need to take Mounjaro for life?

Weight management is often long-term. In SURMOUNT-4, stopping tirzepatide after an initial treatment period led to substantial regain on average, while continuing treatment helped sustain results. The right duration and maintenance plan require individualized review.

7. Does Mounjaro cause muscle loss?

Any substantial weight reduction can include some loss of lean mass. Adequate protein, resistance exercise and appropriate monitoring help prioritize strength and function alongside changes in body weight.

8. Can I take Mounjaro without diabetes?

Yes, for eligible adults meeting the approved chronic weight-management criteria in India, after medical assessment. It is not intended for cosmetic weight loss.

9. What if I have nausea on the starter dose?

Tell your prescriber, especially if symptoms are persistent or affect fluid and food intake. Smaller meals and individualized dietary adjustments may help some patients. Never increase the dose early to accelerate weight loss.

10. Where can I consult for Mounjaro weight loss in Ahmedabad?

For assessment of medical eligibility, treatment monitoring and long-term planning, you can consult Dr. Moxit Shah, DM Endocrinology, at Vishuddha Diabetes, Thyroid, Weight Loss Clinic in Ghatlodiya, Ahmedabad. Appointments: +91 99799 92797.

Personalized Mounjaro weight-loss treatment in Ahmedabad

Successful medical weight loss is not defined by the fastest possible response after four injections. It involves an appropriate diagnosis, a suitable medication, nutrition that protects health, progressive physical activity, symptom management and sustainable follow-up.

At Vishuddha Diabetes, Thyroid, Weight Loss Clinic, Dr. Moxit Shah, DM Endocrinology, offers individualized assessment for diabetes and medical weight-loss management. Appointments can help clarify whether tirzepatide is appropriate, what to monitor during the first month and how to review long-term treatment goals.

Clinic address: Vishuddha Diabetes, Thyroid, Weight Loss Clinic, 104–105, Elite Magnum, Bhuyangdev Cross Road, Opp. Utsav Elegance, Vardhmannagar Society, Ghatlodiya, Ahmedabad, Gujarat 380061, India.
Nearby: Memnagar, Naranpura and Bhuyangdev.
Doctor: Dr. Moxit Shah, DM Endocrinology.
Call: +91 99799 92797.

Medical references

  1. Lilly India: CDSCO Approval of Mounjaro KwikPen for Diabetes and Weight Management (2025).
  2. Mounjaro KwikPen Summary of Product Characteristics (updated September 2026) — initiation, escalation, maintenance and safety.
  3. Jastreboff et al., SURMOUNT-1: Tirzepatide Once Weekly for Weight Management, NEJM (2022).
  4. Garvey et al., SURMOUNT-2: Tirzepatide in Adults with Type 2 Diabetes and Excess Weight, Lancet (2023).
  5. Aronne et al., SURMOUNT-4: Continued Tirzepatide for Maintenance of Weight Reduction, JAMA (2024).
  6. Lilly India: Mounjaro KwikPen Launch and Dated Indian MRPs (12 August 2025).
  7. U.S. Mounjaro Prescribing Information (2026) — additional safety context; local Indian prescribing information governs use in India.

Disclaimer: This article is for general medical education, not a prescription or guarantee of weight-loss outcomes. Mounjaro is a prescription medicine requiring individual clinical assessment. Do not start, stop, escalate, combine or switch weight-loss medicines without your treating clinician’s advice. Seek urgent care for severe symptoms. The price figures above are dated launch MRPs, not current pharmacy quotations.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *